Company news
PYC Therapeutics Limited news in 2024
PYC Therapeutics Limited's news releases, calls and decks from 2024, newest first.
PYC Nominates Fourth Clinical Drug Candidate in PMS Program
December 15, 2024
PYC to Progress Kidney Drug Candidate Into Human Trials
November 26, 2024
Consolidation/Split - PYC
November 11, 2024
RP11 SRC Approves Dose Escalation to Final Patient Cohort
November 4, 2024
First ADOA Patient Dosed in Clinical Trial
October 31, 2024
Interim Update on Progress in RP11 Repeat Dose Trials
October 21, 2024
US FDA Grants Orphan Drug Designation to PYC Drug Candidate
October 20, 2024
Notice of Annual General Meeting/Proxy Form
October 14, 2024
FDA Grants Rare Pediatric Disease Designation to PYC-001
August 29, 2024
Appendix 4E and Audited Financial Statements
August 29, 2024
PYC to Start Human Trials in Second Blinding Eye Disease
August 14, 2024
Visual Improvement in Multiple RP11 Patients
August 11, 2024
RP11 Clinical Trial Update - Amended
August 5, 2024
RP11 Clinical Trial Update
August 4, 2024
Extension of RP11 Single Dose Study Into Multiple Dose Study
July 22, 2024
Initial Dosing Completed in Cohort 1 of RP11 MAD Study
July 16, 2024
Commencement of RP11 Multiple Dose Trial
July 9, 2024
RP11 Drug Candidate Safe and Well Tolerated
June 30, 2024
PMS Drug Candidate Effective In Human Brain Cells
June 6, 2024
RP11 Clinical Trial Dosing Completed in Cohort 4
May 15, 2024
Successful GLP Tox Studies in Second Blinding Eye Disease
May 13, 2024
Presentation of RP11 Clinical Trial Data at ARVO Conference
May 5, 2024
RP11 Drug Candidate Progressing to Mid-Stage Human Trials
April 28, 2024
Kidney Disease Drug Candidate Progressing to Human Trials
April 21, 2024
$74.6 Million Extension of Cash Runway
April 10, 2024
PYC Equity Raising to Raise up to $74.6 Million
March 13, 2024
RP11 Clinical Trial - Dosing Completed in Cohort 3
February 27, 2024
Receipt of $4.5m Collaboration Fee
February 16, 2024
AI Driven Drug Discovery Collaboration with Google Cloud
January 1, 2024
Decks in 2024
- Investor Presentation (November 2024)
Investor deck · 12 slides · Nov 28, 2024
- Technical Presentation (November 2024)
Technical · 17 slides · Nov 22, 2024
- Shareholder Meeting (November 2024)
Shareholder meeting · 16 slides · Nov 13, 2024
- E&P Healthcare Conference 2024
Conference · 9 slides · Sep 26, 2024
- Corporate Update (August 2024)
Corporate update · 23 slides · Aug 30, 2024
- Canaccord Genuity Growth Conference 2024
Conference · 15 slides · Aug 13, 2024
- Bioshares Biotech Summit 2024
Conference · 21 slides · Jul 12, 2024
- Corporate Update (May 2024)
Corporate update · 14 slides · May 9, 2024
- ARVO 2024
Conference · 17 slides · May 6, 2024
- ARVO 2024 (Association for Research in Vision and Ophthalmology)
Conference · 20 slides · May 6, 2024
- Investor Presentation (March 2024)
Investor deck · 41 slides · Mar 14, 2024
- Euroz Hartleys Healthcare Conference 2024
Conference · 12 slides · Feb 6, 2024
- Investor Presentation (February 2024)
Investor deck · 8 slides · Feb 2, 2024